Board reshuffle at Lipocine (NASDAQ: LPCN) as chairman exits, new independent leader named
Rhea-AI Filing Summary
Lipocine Inc. reported that on April 16, 2026, Dr. Spyros Papapetropoulos resigned from its Board of Directors effective immediately. He had served since 2022 as Chairman, Lead Independent Director, and a member of the Board’s compensation committee.
The company stated that Dr. Papapetropoulos resigned due to competing professional commitments and evolving board dynamics arising from differing views on Lipocine’s strategic direction. On April 20, 2026, the Board appointed R. Dana Ono as the new Chairman of the Board and Lead Independent Director, ensuring continuity in independent board leadership.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
Lead Independent Director financial
compensation committee financial
emerging growth company regulatory
strategic direction financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
Commission
File No.
(State or other jurisdiction of incorporation) |
(IRS Employer Identification Number) |
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
Former name or former address, if changed since last report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 16, 2026, Spyros Papapetropoulos informed the Board of Directors (the “Board”) of Lipocine Inc. (the “Company”) that he resigned as a member of the Board effective immediately. Dr. Papapetropoulos has served as a member of the Board since 2022 and was the Board’s Chairman and Lead Independent Director and a member of the Board’s compensation committee. On April 20, 2026, the Board appointed R. Dana Ono as Chairman of the Board and Lead Independent Director.
Dr. Papapetropoulos resigned due to competing professional commitments and evolving board dynamics arising from differing views on the Company’s strategic direction.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LIPOCINE INC. | ||||
| Date: | April 21, 2026 | By: | /s/ Mahesh V. Patel | |
| Mahesh V. Patel | ||||
| President and Chief Executive Officer | ||||